The effect of cuts on access to left ventricular assist device programs

Medicare physician fee schedule cuts can look like a budgeting dispute, yet for people with advanced heart failure they may translate into fewer appointments, longer surgical queues and reduced access to left ventricular assist device programmes. An LVAD is a durable pump that provides mechanical circulatory support for a weakened left ventricle. In the United States, the policy issue extends beyond implant operating time to surgeons, coordinators, intensive care, blood products, monitoring and transplant teams. Access can shrink even when the device itself remains available.

For Australian patients and clinicians, US policy is not directly applicable, but the funding lesson is immediate: lowering the price of physician work does not remove the fixed costs of complex care. Australia operates through the Medicare Benefits Schedule, state and territory public hospitals, and private health insurance, with specialist referrals shaping entry to treatment. The question is therefore not simply whether an LVAD can be bought, but whether a safe programme remains available, geographically reachable and able to provide lifelong support.

How fee reductions reach heart failure services

The US policy case is set out by the Campaign for Patient Access, launched by the American College of Cardiology to oppose Medicare physician fee schedule cuts affecting cardiovascular care. The campaign also tracks legal and legislative responses to the policy. Its concern extends beyond the price of a consultation: lower payments can leave hospitals and physician groups with less income for complex cases and the infrastructure around them. A large centre may absorb a modest reduction, while a lower-volume service can struggle to retain the staffing that makes an LVAD programme viable.

Australian funding is arranged differently, so identical outcomes should not be assumed. Medicare rebates, Commonwealth funding to public hospitals through national agreements, state and territory budgets, and private-insurance payments can intersect. Capital equipment is also procured through hospital and supply contracts rather than bought directly by most patients. A cardiology practice may refer someone to a cardiothoracic centre but cannot control that centre’s theatre capacity, intensive care access, device stock or multidisciplinary staffing.

Access should be measured at several points: time to specialist review, time to implantation, surgical availability and continuity after discharge. A programme able to implant but unable to manage infection, thrombosis, arrhythmia or pump failure is not fully functional. This matters in advanced heart failure, where deterioration can be rapid and an LVAD may provide bridge to transplant, bridge to recovery or destination therapy.

Why an LVAD programme is a whole system

An LVAD programme is a care pathway, not a device-dispensing service. Evaluation may combine echocardiography, cardiac imaging, exercise testing, kidney and liver function assessment, nutrition review and multidisciplinary goals-of-care discussions. Surgery requires cardiopulmonary support, anticoagulation expertise, intensive care and rehabilitation. Long-term success also depends on flow and pressure monitoring, wound care, medication access and a rapid response to alarms.

These capabilities are concentrated in metropolitan hospitals. Melbourne and Sydney have advanced cardiac referral networks capable of supporting device therapy, while patients in Brisbane, Adelaide, Perth and regional areas may depend on fewer tertiary centres. A national service can be clinically excellent, but distance remains an access barrier: families may need accommodation, unpaid leave, flights and local follow-up arranged around a short surgical window.

Australian pathways must also respect treatment goals and practical circumstances. A patient may be referred from a regional town to a capital-city implant team. That separation is manageable when referrals and records move quickly, but burdensome when appointments are repeated or discharge instructions do not fit local resources. Aboriginal and Torres Strait Islander patients and communities require culturally safe care and locally coordinated support, not an assumption that standard metropolitan arrangements will suit every family.

What patients experience when capacity contracts

Reduced capacity rarely arrives as an obvious closure. It may appear as a restricted implant date, a longer wait for advanced-heart-failure review, fewer clinic sessions or dependence on a small number of clinicians. A programme can still appear on a website while timely treatment becomes unavailable. With deteriorating cardiomyopathy, delay may also mean a more hurried referral, less time for planning and a higher chance that the preferred treatment option changes.

The burden falls unevenly. A patient with stable support at home may manage travel better than someone living alone or requiring home oxygen, dialysis, complex nursing or regular community follow-up. Regional patients can lose local cardiac rehabilitation when staff focus shifts toward implant surveillance. Informal carers may absorb transport, medication administration and monitoring, while work and schooling are interrupted. Counting only the operation misses these wider costs.

Trust can weaken if savings are presented as accounting changes without explaining their effect on appointments. Transparent reporting can reveal growing demand and temporary constraints, allowing patients, families, cardiologists and surgeons to distinguish a safety problem from a commercial decision to withdraw a service. That evidence should guide responses, while every centre must retain safe staffing and governance rather than be pressured to operate beyond its limits.

Funding choices can widen or narrow access

Policy responses should protect continuity rather than simply reimburse the highest-cost procedure. Options include targeted access payments, bundled implant funding, time-limited regional service support and pooled arrangements for device follow-up. Each involves trade-offs. Bundled payments can encourage coordination but underpay complex cases; grants can preserve capacity but expire; broad subsidies improve access but may preserve inefficient pathways.

Clear explanation matters because funding choices become symbols of access. Reporting on high-speed rail updates illustrates how infrastructure decisions affect regional connections, even though the service is unrelated. An LVAD funding decision carries a similar message: whether highly specialised cardiovascular care is treated as essential infrastructure or an optional service that can be trimmed when budgets tighten.

In Australia, responses must fit the division of responsibility between the Commonwealth and states and territories. Medicare can adjust rebates and national funding, while state and territory governments manage public hospitals and some community services. Private insurers influence affordability and hospital participation, and TGA regulation and ARTG listing requirements shape lawful device supply. Procurement, staff training and follow-up must be considered together; a lower purchase price alone does not create a sustainable programme.

Comparing ways to protect access

A useful comparison asks what each mechanism protects, what it risks and how results can be reviewed. The goal is not to preserve every arrangement at any price. It is to maintain timely, safe treatment and reduce avoidable regional inequality while allowing transparent review of cost and outcomes.

Funding mechanism	Principal strength	Principal risk	Required safeguard
Broad fee reduction	Reduces expenditure quickly	Service capacity and access erode	Minimum access, staffing and safety standards
Bundled implant payment	Encourages joined-up episode care	Long-term complex care is underfunded	Case-mix adjustment and periodic review
Time-limited capacity grant	Preserves a threatened service	Temporary fix without a transition	Published end date and sustainable handover
Regional access fund	Supports travel and local follow-up	Fragmented programmes and weak accountability	Shared protocols, coordinator and outcome measures

For Australia, a blended approach is more plausible than an across-the-board response. National payments could support the high-risk implant episode, state and territory funding could sustain local staffing and rehabilitation, and targeted funds could address travel, remote monitoring and areas without a nearby implant centre. Private insurance should not create a faster queue when teams treat the public sector too. Pilots should measure waiting time, readmission, complications, patient travel burden and equitable access.

Actions to preserve advanced-heart-failure capacity

These actions offer a practical way to protect advanced-heart-failure capacity:

• Measure access end to end, publishing waiting times from referral through implantation and follow-up rather than reporting only procedure volumes.
• Fund the entire care pathway, covering device procurement, coordinators, intensive care, rehabilitation, monitoring and rapid clinical support.
• Protect regional pathways with agreed referral protocols, teleconsultations, travel assistance and local cardiac follow-up linked to the implant centre.
• Use transparent criteria for programme changes, with clinical and community consultation before capacity, hours or service locations are reduced.
• Review outcomes and costs regularly, adjusting bundled payments and grants when they underfund complex cases or reward low-quality care.
• Give patients and carers a clear escalation route for alarms, complications and access delays, supported by a named coordinator and written aftercare plans.

---

Patients and families can use the linked campaign resources to understand the policy and, where appropriate, share a personal account of delays, travel or aftercare barriers. Clinicians can keep referral information current, document changes in symptoms and treatment goals, and involve cardiothoracic teams early when advanced heart failure is progressing.

Decision-makers should hear directly from people who rely on these services. Before changing reimbursement or capacity, publish the projected effect on appointments, travel, follow-up and regional coverage, then invite patients, carers, rural clinicians and Aboriginal and Torres Strait Islander communities to respond. That evidence can support the campaign’s central objective: preserving access to high-quality cardiovascular care while keeping its cost transparent and accountable.